Avacta and Tempus Join Forces to Advance AI-Driven Drug Development  in Oncology

Life sciences company Avacta Therapeutics (LON: AVCT) announced a strategic partnership with Tempus AI, Inc. (Nasdaq: TEM), an artificial intelligence-driven precision medicine firm.

The AIM company explained in its press release that the collaboration aims to accelerate the development of innovative oncology treatments.

The partnership is expected to provide Avacta with access to Tempus' multimodal datasets containing primary tumour samples and associated clinical data from over 200,000 patients across a wide range of cancer indications.

The collaboration is designed to leverage the data “to characterise the deep biology of the tumor microenvironment and fibroblast activation protein (FAP) activity upon which its pre|CISION technology is based.”

The knowledge will be used to inform the development of Avacta's pre|CISION platform, which targets powerful anti-tumour payloads directly to the tumour.

Avacta has recently expanded its pre|CISION platform with two new preclinical new programs, AVA6103 and AVA7100. The programs leverage the platform's ability to deliver potent anti-tumour effects while minimising exposure to healthy tissues.

Through the collaboration with Tempus AI, Avacta is aiming to identify the optimal patient populations for its clinical programs by leveragingthe company's analytical support and computational biology expertise.

It is expected to enable faster and more efficient clinical development, ultimately increasing the probability of success.

“The Tempus AI real-world database and industry-leading AI capabilities will enable us to better assess the specific patient population most likely to respond to our pre|CISION® therapies, enabling faster, smarter clinical development with the highest probability of success,” commented Christina Coughlin, CEO of Avacta. 

Meanwhile, Tempus AI's Chief Scientific Officer, Kate Sasser, added: “Tempus was created to build one of the world's largest libraries of multimodal data and an operating system to make those data accessible and useful. This collaboration with Avacta is another example of our execution of that vision, and we are thrilled to partner with Avacta in support of their efforts to bring game-changing new therapies to patients in need.”